Literature DB >> 10526445

[Ocular manifestations in sarcoidosis].

E Dróbecka1, M Swituła, J Godowska, I Skórska, M Płodziszewska, J Szopiński.   

Abstract

PURPOSE: The ophthalmic examination of patients with diagnosed systemic sarcoidosis.
MATERIAL AND METHODS: 33 patients (17 women, 16 men), aged 22-60 years had ophthalmic examination (visual acuity, anterior and posterior segment evaluation, applanation tonometry). In 8 patients repeated examination was performed (duration of observation: 2-31 months).
RESULTS: In 27 patients no characteristic features of ocular sarcoidosis were found. In 6 persons (18.2%) variety of ocular lesions was recognized (nodular infiltrations of the eyelids, chronic uveal inflammation, signs of anterior and posterior uveitis in the past, optic disc oedema). In 3 cases ocular lesions preceded the signs of systemic sarcoidosis. This emphasizes the importance of the routine ophthalmic examination of patients with suspected or proven sarcoidosis.

Entities:  

Mesh:

Year:  1999        PMID: 10526445

Source DB:  PubMed          Journal:  Klin Oczna        ISSN: 0023-2157


  2 in total

1.  A Retrospective Observational Study of Uveitis in a Single Center in Poland with a Review of Findings in Europe.

Authors:  Joanna Brydak-Godowska; Katarzyna Moskal; Piotr K Borkowski; Mariusz Przybyś; Monika Turczyńska; Dariusz Kęcik
Journal:  Med Sci Monit       Date:  2018-12-03

2.  Diagnosis and Detection of Sarcoidosis. An Official American Thoracic Society Clinical Practice Guideline.

Authors:  Elliott D Crouser; Lisa A Maier; Kevin C Wilson; Catherine A Bonham; Adam S Morgenthau; Karen C Patterson; Eric Abston; Richard C Bernstein; Ron Blankstein; Edward S Chen; Daniel A Culver; Wonder Drake; Marjolein Drent; Alicia K Gerke; Michael Ghobrial; Praveen Govender; Nabeel Hamzeh; W Ennis James; Marc A Judson; Liz Kellermeyer; Shandra Knight; Laura L Koth; Venerino Poletti; Subha V Raman; Melissa H Tukey; Gloria E Westney; Robert P Baughman
Journal:  Am J Respir Crit Care Med       Date:  2020-04-15       Impact factor: 21.405

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.